Kohjin Bio Co., Ltd.

Tokyo Stock Exchange 177A.T

Kohjin Bio Co., Ltd. Free Cash Flow Yield on January 31, 2025: 3.36%

Kohjin Bio Co., Ltd. Free Cash Flow Yield is 3.36% on January 31, 2025, a 79.44% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Kohjin Bio Co., Ltd. 52-week high Free Cash Flow Yield is 3.71% on August 05, 2024, which is 10.26% above the current Free Cash Flow Yield.
  • Kohjin Bio Co., Ltd. 52-week low Free Cash Flow Yield is 1.55% on July 17, 2024, which is -53.73% below the current Free Cash Flow Yield.
  • Kohjin Bio Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is 2.75%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
SV Wall Street
Tokyo Stock Exchange: 177A.T

Kohjin Bio Co., Ltd.

CEO Mr. Takahito Nakamura
IPO Date April 25, 2024
Location Japan
Headquarters 5-1-3
Employees 159
Sector Health Care
Industries
Description

Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums. In addition, the company offers normal human blood, serum, and plasma; pathological human serum; preserved animal blood; defibrinated and hemolyzed animal blood; animal serum and plasma; and other custom-designed products, such as eagle medium. Further, the company engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. The company was incorporated in 1981 and is based in Sakado, Japan.

StockViz Staff

February 1, 2025

Any question? Send us an email